Business Context and Reporting Period
Company: Integer Holdings Corp (ITGR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 27, 2025
Business Overview: Integer is a medical device contract development and manufacturing organization (CDMO) serving cardiac rhythm management, neuromodulation, and cardio/vascular markets. The company operates as a single segment.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6M 2025 | 6M 2024 |
|---|---|---|---|---|
| Sales | $476,494 | $427,886 | $913,886 | $835,682 |
| Gross Profit | $129,152 | $117,377 | $249,470 | $225,650 |
| Gross Margin | 27.1% | 27.4% | 27.3% | 27.0% |
| Operating Income | $59,338 | $54,494 | $108,890 | $93,195 |
| Net Income (Continuing Ops) | $37,009 | $31,207 | $14,544 | $51,798 |
| Diluted EPS (Continuing Ops) | $1.04 | $0.88 | $0.41 | $1.47 |
| Operating Cash Flow (6M) | $75,138 (2025) vs $70,474 (2024) | |||
| Cash & Equivalents (End of Period) | $23,135 | |||
| Total Debt (Net Carrying) | $1,202,495 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 11.4% in Q2 and 9.4% in the first six months of 2025 compared to 2024. Growth was driven by the Cardio & Vascular segment (+24% in Q2) and contributions from recent acquisitions (Precision Coating and VSi Parylene). The "Other Markets" segment declined 38% due to the planned exit of the Portable Medical business.
- Profitability Impact: While Q2 net income increased 18.6% year-over-year, the six-month net income decreased 71.9% to $14.5 million. This significant decline is primarily due to a $46.7 million non-cash induced conversion expense recorded in Q1 2025 related to the exchange of 2028 Convertible Notes.
- Debt Restructuring: In March 2025, the company issued $1.0 billion in 2030 Convertible Notes. Proceeds were used to exchange $383.7 million of 2028 Convertible Notes and pay down the Term Loan A facility. Total debt principal increased, but the mix shifted toward lower-cost fixed-rate debt.
- Acquisitions: The company completed two acquisitions in early 2025: Precision Coating LLC ($153.5M consideration) and VSi Parylene ($24.0M consideration), adding surface coating capabilities.
Guidance, Outlook, and Risks
- Outlook: Management expects the Portable Medical market exit to conclude in 2025. The company anticipates continued growth in Cardio & Vascular and Cardiac Rhythm Management segments driven by new product ramps and emerging customers.
- Liquidity: As of June 27, 2025, the company had $23.1 million in cash and $784.7 million in available borrowing capacity under its Revolving Credit Facility. Management believes cash flows and borrowing capacity are sufficient for the next 12 months.
- Convertible Notes: The 2028 Convertible Notes became eligible for conversion by holders in Q2 2025 due to stock price performance. The company intends to refinance any conversion obligations using its Revolving Credit Facility. The 2030 Convertible Notes are not currently convertible.
- Risks: Key risks include dependence on a limited number of customers, supply chain disruptions, geopolitical factors, and the potential dilution from convertible note conversions. The company is also evaluating the impact of new U.S. tax legislation (OBBBA) signed in July 2025.
Investor Verification Checklist
- Induced Conversion Expense: Verify the $46.7 million non-cash charge in Q1 2025 and its impact on the effective tax rate (55.4% for 6M 2025).
- Debt Covenants: Confirm compliance with the Total Net Leverage Ratio (currently ~2.7:1.0) and Interest Coverage Ratio (currently ~10.4:1.0) under the Senior Secured Credit Facilities.
- Convertible Note Conversion: Monitor the status of the 2028 Convertible Notes, which remain eligible for conversion, and the company's ability to fund potential cash settlements via the Revolver.
- Acquisition Integration: Assess the revenue contribution and integration progress of the Precision and VSi acquisitions, which contributed $27.2 million in sales during the first six months of 2025.
- Portable Medical Exit: Track the decline in "Other Markets" revenue as the company winds down the Portable Medical business line.